Home › Funds › NEXTBio Capital Management LP › ZLAB
NEXTBio Capital Management LP position in ZLAB
ZAI LAB LTD · Health Care
NEXTBio Capital Management LP reported holding 238,362 shares of ZLAB (ZAI LAB LTD) in its Q3 2026 13F filing — a position valued at US$6.3M, representing 2.73% of its reported portfolio and ranking #15 among its reported holdings. NEXTBio Capital Management LP has disclosed ZLAB holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How NEXTBio Capital Management LP's ZLAB position evolved
NEXTBio Capital Management LP first disclosed a stake in ZLAB in Q4 2025 at 163,362 shares (US$2.9M). The position peaked in Q3 2026 at 238,362 shares, worth US$6.3M. Across 4 filings, NEXTBio Capital Management LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 238,362 shares valued at US$6.3M — an increase of 55,000 shares quarter over quarter.. Notable position changes include a 30% increase in Q3 2026 (shares fell 7% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 163.36K | $2.88M | New |
| Q1 2026 | 183.36K | $3.45M | Add |
| Q2 2026 | 183.36K | $3.48M | Hold |
| Q3 2026 | 238.36K | $6.28M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ZLAB and 13F data
ZLAB (ZAI LAB LTD) is a Health Care company. 17 other funds we track also report a position in ZLAB — the largest reported positions include RTW INVESTMENTS, LP (US$124.9M), TCG Crossover Management, LLC (US$116.6M), RA CAPITAL MANAGEMENT, L.P. (US$109.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ZLAB
- RTW INVESTMENTS, LP 6.57M sh · $124.91M · Q2 2026
- TCG Crossover Management, LLC 6.14M sh · $116.61M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 5.74M sh · $109.13M · Q2 2026
- ADAR1 Capital Management, LLC 3.37M sh · $64.01M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.90M sh · $36.14M · Q2 2026
- Patient Square Capital LP 591.51K sh · $15.58M · Q3 2026
- Rock Springs Capital Management LP 814.71K sh · $15.48M · Q2 2026
- C WorldWide Group Holding A/S 510.00K sh · $13.43M · Q3 2026
- B Group, Inc. 450.65K sh · $8.56M · Q2 2026
- NAN FUNG TRINITY (HK) Ltd 293.97K sh · $7.74M · Q3 2026
More on NEXTBio Capital Management LP
FAQ
How long has NEXTBio Capital Management LP held ZLAB?
NEXTBio Capital Management LP has disclosed ZLAB holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is NEXTBio Capital Management LP's current position in ZLAB?
As of Q3 2026, NEXTBio Capital Management LP holds 238.36K shares of ZLAB (ZAI LAB LTD), valued at $6.28M, representing 2.73% of its reported portfolio and ranking #15.
Has NEXTBio Capital Management LP been buying or selling ZLAB?
In the latest 13F filing (Q3 2026), NEXTBio Capital Management LP increased its position in ZLAB. The position peaked in Q3 2026 at 238.36K shares.
Which other funds hold ZLAB?
Other major institutional holders of ZLAB include RTW INVESTMENTS, LP, TCG Crossover Management, LLC, RA CAPITAL MANAGEMENT, L.P., among 17 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.